Toll-like receptor 9 agonists as cancer therapeutics

被引：53
|
作者：
Holtick, Udo [1 ,2 ]
Scheulen, Max E. [3 ]
von Bergwelt-Baildon, Michael S. [1 ,2 ]
Weihrauch, Martin R. [1 ,2 ]
机构：
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
[2] Univ Cologne, Lab Transplantat & Tumor Immunol, Max Eder Grp, D-50924 Cologne, Germany
[3] Univ Essen Gesamthsch, W German Canc Ctr, Dept Med Canc Res, Essen, Germany
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 03期
关键词：
cancer; immunotherapy; TLR9; agonists; vaccine; BACTERIAL CPG-DNA; PHASE-II TRIAL; NF-KAPPA-B; T-CELLS; IMMUNOSTIMULATORY ACTIVITY; DENDRITIC CELLS; MOLECULAR-PATTERNS; ANTITUMOR-ACTIVITY; INNATE IMMUNITY; GROWTH-FACTOR;
D O I：
10.1517/13543784.2011.553187
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered: This review summarizes TLR9 signaling and the impact of TLR9 agonists on the immune response. The most recent experimental and clinical data are analyzed as well as the development of new TLR9 agonists in current clinical trials. Expert opinion: Application of TLR9 agonists, in particular, combination strategies with chemo- or radiotherapy seem a promising and efficient immunotherapeutic approach in cancer patients even with refractory disease. Simultaneous application of TLR9 agonists aims at supporting the patient's immune response and overcoming specific immunosuppressant strategies developed by tumors. Combinatory approaches of the future might also seek for synergism of TLR9 agonists with other immunomodulatory strategies such as B-cell activation using the CD40--CD40L system.
引用
收藏
页码：361 / 372
页数：12
相关论文
共 50 条
  • [1] Toll-Like Receptor 9 Agonists in Cancer
    Karapetyan, Lilit
    Luke, Jason J.
    Davar, Diwakar
    ONCOTARGETS AND THERAPY, 2020, 13 : 10039 - 10060
  • [2] Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer
    Zhang, Christine
    Ben, Atheena
    Reville, Jade
    Calabrese, Victoria
    Villa, Nina Nicole
    Bandyopadhyay, Mausumi
    Dasgupta, Subhajit
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2015, 15 (09) : 1134 - 1140
  • [3] Toll-like receptor agonists in cancer therapy
    Adams, Sylvia
    IMMUNOTHERAPY, 2009, 1 (06) : 949 - 964
  • [4] Toll-like receptor agonists as cancer vaccine adjuvants
    Jeon, Donghwan
    Hill, Ethan
    Mcneel, Douglas G.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [5] The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
    Martinsen, Janne Tegder
    Gunst, Jesper Damsgaard
    Hojen, Jesper Falkesgaard
    Tolstrup, Martin
    Sogaard, Ole Schmeltz
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [6] The future of toll-like receptor therapeutics
    Parkinson, Tanya
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2008, 10 (01) : 21 - 31
  • [7] Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics
    Kaur, Arshpreet
    Baldwin, Jeremy
    Brar, Deshkanwar
    Salunke, Deepak B.
    Petrovsky, Nikolai
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2022, 70
  • [8] Synthesis and immunological activities of novel agonists of toll-like receptor 9
    Struthers, Mary
    Bett, Andrew J.
    Wisniewski, Thomas
    Dubey, Sheri A.
    Precopio, Melissa
    Jiang, Weiwen
    Sun, Zhenhua
    Wang, Hao
    Nowak, Ireneusz
    Putta, Mallikarjuna R.
    Yu, Dong
    Tang, Jimmy X.
    Kandimalla, Ekambar R.
    Agrawal, Sudhir
    Casimiro, Danilo R.
    CELLULAR IMMUNOLOGY, 2010, 263 (01) : 105 - 113
  • [9] The role of Toll-like receptor 9 in gynecologic cancer
    Fehri, E.
    Ennaifer, E.
    Rhouma, R. Bel Haj
    Guizani-Tabbane, L.
    Guizani, I.
    Boubaker, S.
    CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2016, 64 (03) : 155 - 159
  • [10] Toll-Like Receptor Agonists Are They Good Adjuvants?
    Gnjatic, Sacha
    Sawhney, Nikhil B.
    Bhardwaj, Nina
    CANCER JOURNAL, 2010, 16 (04) : 382 - 391
12345